News

Nanobind is an inexpensive thermoplastic nanomaterial developed for high integrity DNA and RNA extraction. Its hierarchical structure of microscale folds topped by nanoscale wrinkles creates a high binding

The 2014 SWF Research Grants will support research conducted by two prominent investigators over two years. The grants are the largest awarded by the Sturge-Weber Foundation to date.

The acquisition is subject to receipt of customary regulatory approvals and approval by Furiex shareholders. Forest concurrently announced that it has entered into an agreement with Royalty Pharma

Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

The merger, in combination with an expansive capital investment program, will create product development and production capabilities across 600,000ft² of manufacturing space. The combined scale and breadth of

The agreement includes cell line optimization, analytical development and manufacturing scale-up activities for Omni Bio’s leading AAT Fc fusion protein with the goal of providing cGMP product to

As part of the deal, REGENX granted AAVLife an exclusive worldwide license, with rights to sublicense, to deliver its NAV rAAVrh10 vector via non CNS routes to treat

The randomized, double masked, placebo controlled Phase II trial has enrolled a total of 142 treatment naive wet-AMD patients at more than 20 clinical sites in the US.

Actavis maintains that the FDA improperly awarded sole exclusivity on generic Celebrex to Teva Pharmaceutical Industries despite an earlier ruling from the US Court of Appeals for the